Expert Opinion on Managing Chronic HCV in Patients with Non-Hodgkin Lymphoma and other Extrahepatic Malignancies

被引:8
|
作者
Ferri, Clodoveo [1 ]
Feld, Jordan J. [2 ]
Bondin, Mark [3 ]
Cacoub, Patrice [4 ,5 ,6 ,7 ,8 ]
机构
[1] Univ Modena & Reggio Emilia, Modena, Italy
[2] Univ Toronto, Toronto Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada
[3] AbbVie Inc, Chicago, IL USA
[4] Sorbonne Univ, UPMC Univ Paris 06, UMR 7211, Paris, France
[5] Sorbonne Univ, Inflammat Immunopathol Biotherapy Dept DHU i2B, UPMC Univ Paris 06, Paris, France
[6] INSERM, UMR S 959, F-75013 Paris, France
[7] CNRS, FRE3632, F-75005 Paris, France
[8] Grp Hosp Pitie Salpetriere, AP HP, Dept Internal Med & Clin Immunol, F-75013 Paris, France
关键词
HEPATITIS-C-VIRUS; MARGINAL ZONE LYMPHOMA; B-CELL LYMPHOMAS; ANTIVIRAL THERAPY; HEPATOCELLULAR-CARCINOMA; THYROID-CANCER; LICHEN-PLANUS; INFECTION; RISK; MANIFESTATIONS;
D O I
10.3851/IMP3250
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
HCV is a carcinogen that is well established as a major risk factor for hepatocellular carcinoma. Evidence that HCV plays a role in the development of extrahepatic malignancies is less robust; however, epidemiological studies have consistently demonstrated an association between HCV infection and B-cell non-Hodgkin lymphoma (NHL). The strongest evidence for a link between HCV and tumouri-genesis is the clear association between viral eradication, as indicated by achievement of sustained virological response, and remission of B-cell NHL. All-oral direct-acting antiviral-based therapies are effective in patients with HCV-associated NHL and well tolerated. For this reason, it is important that clinicians assess HCV-infected patients for HCV-associated extrahepatic malignancies so patients can receive timely diagnosis and treatment.
引用
收藏
页码:23 / 33
页数:11
相关论文
共 50 条
  • [1] HCV and non-Hodgkin lymphoma
    Hanley, J
    Jarvis, L
    Simmonds, P
    Parker, A
    Ludlam, C
    LANCET, 1996, 347 (9011): : 1339 - 1339
  • [2] HCV and non-Hodgkin lymphoma
    Pioltelli, P
    Zehender, G
    Monti, G
    Monteverde, A
    Galli, M
    LANCET, 1996, 347 (9001): : 624 - 625
  • [3] CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies
    Dilek, I
    Ayakta, H
    Demir, C
    Meral, C
    Ozturk, M
    CLINICAL AND LABORATORY HAEMATOLOGY, 2005, 27 (01): : 51 - 55
  • [4] Expert Opinion on Managing Chronic HCV in Patients with Neuropsychiatric Manifestations
    Forton, Daniel
    Weissenborn, Karin
    Bondin, Mark
    Cacoub, Patrice
    ANTIVIRAL THERAPY, 2018, 23 : 47 - 55
  • [5] Expert Opinion on Managing Chronic HCV in Patients with Cardiovascular Disease
    Vassalle, Cristina
    Petta, Salvatore
    Pepe, Alessia
    Craxi, Antonio
    Bondin, Mark
    Cacoub, Patrice
    ANTIVIRAL THERAPY, 2018, 23 : 35 - 46
  • [6] Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma
    Wang, Yucai
    Wang, Yanru
    Thanarajasingam, Gita
    Thompson, Carrie A.
    Habermann, Thomas M.
    Nowakowski, Grzegorz S.
    Wang, Michael
    BLOOD, 2017, 130
  • [7] Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis
    Zignego, Anna Linda
    Pawlotsky, Jean-Michel
    Bondin, Mark
    Cacoub, Patrice
    ANTIVIRAL THERAPY, 2018, 23 : 1 - 9
  • [8] Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection
    Duberg, AS
    Nordström, M
    Törner, A
    Reichard, O
    Strauss, R
    Janzon, R
    Bäck, E
    Ekdahl, K
    HEPATOLOGY, 2005, 41 (03) : 652 - 659
  • [9] Primary non-Hodgkin's lymphoma of the extrahepatic bile duct
    Khozeimeh N.
    Bhatti T.
    Ponsky T.A.
    Cheson B.D.
    Brody F.
    Lin P.P.
    Journal of Gastrointestinal Cancer, 2012, 43 (Suppl 1) : S46 - S49
  • [10] Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus
    Adinolfi, Luigi Elio
    Jacobson, Ira
    Bondin, Mark
    Cacoub, Patrice
    ANTIVIRAL THERAPY, 2018, 23 : 11 - 21